AMGN (Amgen Inc.) חוב לטווח קצר להון

Amgen Inc. is expanding its capital through the acquisition of biotech startups and partnerships with clinics. The GURU.Markets website provides a short-term accounts payable to equity ratio, where the 0.93 mark reflects the current state. Balance sheet stability depends on the renewal of the patent portfolio, while leadership is driven by genetic developments in cardiology and oncology treatments.

The scale of the biotechnology business of Amgen Inc. (AMGN) is reflected in the dynamics of the short-term debt-to-equity ratio. This indicator compares obligations with maturities exceeding one year against equity to assess solvency. The calculation reveals the company's exposure to interest rate and currency risks when financing innovation. A steady decline in this metric confirms the financial stability necessary to protect the biosimilars portfolio and navigate FDA trials.